News Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Real-time Estimate Cboe BZX Other stock markets 11:30:04 2024-04-16 am EDT			5-day change	1st Jan Change
37.54 ^USD	+0.90%		-4.87%	+73.19%

Mar. 18	Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	CI
Mar. 07	North American Morning Briefing : Powell Still in -2-	DJ

Summary

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Spyre Therapeutics Announces Grants of Inducement Awards	Apr. 01	PR
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	Mar. 17	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Spyre Therapeutics Announces Grants of Inducement Awards	Mar. 04	AQ
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Spyre Therapeutics Announces Grants of Inducement Awards	Mar. 01	PR
Spyre Therapeutics: Q4 Earnings Snapshot	Feb. 29	AQ
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 29	PR
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference	Feb. 26	PR
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation	Feb. 09	AQ
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors	Feb. 06	AQ
Spyre Therapeutics, Inc. Announces Board Changes	Feb. 05	CI
Spyre Therapeutics Announces Grants of Inducement Awards	Feb. 02	PR
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	Dec. 26	CI
Spyre Therapeutics Announces Grants of Inducement Awards	Dec. 22	PR
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million	Dec. 08	MT
Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors	Dec. 06	CI
Spyre Therapeutics to Present at Upcoming Investor Conference	Nov. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Summary

Filters